What is the mechanism of action of IGF-1 LR3?

Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. For healthspan and biological-age applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Binds the IGF-1 receptor with full agonist activity. The longevity / hallmarks of aging interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What is the standard dosing protocol for IGF-1 LR3?

Conventional IGF-1 LR3 dosing is 20-50 mcg 1-2x daily subq via subq. For healthspan and biological-age use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

How should IGF-1 LR3 be stored and reconstituted?

Lyophilised IGF-1 LR3 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What should I look for in IGF-1 LR3 sourcing and quality?

Acceptable IGF-1 LR3 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 9111 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What are the safety considerations for IGF-1 LR3?

Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy. For healthspan and biological-age use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. IGF-1 LR3's ~20-30 hr (vs ~10 min for native IGF-1) pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

Home/ Compounds/ IGF-1 LR3

IGF-1 LR3

Longevity

For users tracking biological age and healthspan-relevant biomarkers, IGF-1 LR3 sits within a multi-component longevity framework spanning hallmarks-of-aging from cellular (telomere, senescence, mitochondrial) through integrative (inflammaging, nutrient sensing). A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day. Cycle-based dosing over 8-12 weeks with pre-post biomarker tracking is the longevity-research convention.

Longevity / Hallmarks of Aging Applications

Telomere SupportCellular ReprogrammingInflammagingNutrient SensingSenescence Modulation

Key Takeaways

Longevity lens: IGF-1 LR3 maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Binds the IGF-1 receptor with full agonist activity.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 20-50 mcg 1-2x daily subq dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. Hallmarks-of-aging mapping for IGF-1 LR3: which of the nine hallmarks does this mechanism engage? The subsections below address IGF-1 LR3's mapping to the hallmark framework, its effects on cellular reprogramming and gene expression, healthspan biomarker movement, and the cycle-based versus continuous dosing question that frames longevity-research protocol design.

Mapping to the hallmarks of aging

IGF-1 LR3's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. This places its dominant contribution in the core hallmarks (cellular and molecular) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after IGF-1 LR3 cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Cycle-based versus continuous dosing

IGF-1 LR3's longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.

Longevity / Hallmarks of Aging Applications

NAD+ Metabolism

For nad+ metabolism as a longevity-relevant endpoint, IGF-1 LR3 is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Epigenetic Aging

IGF-1 LR3's contribution to epigenetic aging as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Telomere Support

Telomere Support maps to one of the hallmarks of aging and is one of the dimensions on which IGF-1 LR3 is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Stem Cell Function

For stem cell function as a longevity-relevant endpoint, IGF-1 LR3 is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	20-50 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	12-50 mcg	4–6 weeks initial cycle
Longevity focus	SubQ	20-50 mcg	1-2x daily SubQ
Maintenance phase	SubQ	14-50 mcg	Ongoing with periodic pauses

Dose timing for IGF-1 LR3 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

IGF-1 LR3 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

IGF-1 LR3 + Epithalon: Identified by Khavinson in St. Pairs naturally with IGF-1 LR3's mechanism in longevity / hallmarks of aging protocols.
IGF-1 LR3 + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with IGF-1 LR3's mechanism in longevity / hallmarks of aging protocols.
IGF-1 LR3 + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with IGF-1 LR3's mechanism in longevity / hallmarks of aging protocols.
IGF-1 LR3 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with IGF-1 LR3's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Unapproved (research reagent) Research: Animal models; off-label use widespread

Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy.

Lens-specific safety considerations for longevity / hallmarks of aging use of IGF-1 LR3: Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Long-R3 IGF-I — properties and uses

PMID 1429592

Supporting

IGF-1 LR3 muscle effects

PMID 10393945

IGF-1 LR3 vs Related Peptides

Compound	Profile	Onset	Best For
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Best stack pairing for longevity?

Layered protocols cover multiple hallmarks of aging simultaneously: pineal/telomere (epithalon), thymic/immune (thymalin), mitochondrial (MOTS-c, NAD+), ECM and gene expression (GHK-Cu), and metabolic flexibility (metformin-class or GLP-1-class as appropriate). IGF-1 LR3 contributes to its specific hallmark layer in this multi-component framework.

Does IGF-1 LR3 interact with rapamycin, metformin, or other longevity stacks?

Most peptide compounds are compatible with the standard longevity small-molecule stack (rapamycin, metformin, NAD precursors, senolytics in pulsed protocols). Interactions where present are typically additive rather than competitive. Verify case-specifically with a longevity-informed clinician.

How do I know if IGF-1 LR3 is working?

Track outcome metrics that match the compound's primary mechanism: epigenetic age (DNA methylation panels), inflammatory markers (hsCRP, IL-6), metabolic flexibility (HbA1c, fasting insulin, HOMA-IR), body composition (DEXA), and subjective markers (sleep depth, recovery, well-being). Paired pre-post measurement around cycles is the standard framework.

When in life should I start IGF-1 LR3?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

Should I cycle IGF-1 LR3?

Standard cycle for IGF-1 LR3 is 8–12 weeks of 1-2x daily subq 20-50 mcg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to IGF-1 LR3's ~20-30 hr (vs ~10 min for native IGF-1) half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

How long until I see results from IGF-1 LR3?

Acute effects from IGF-1 LR3 appear within hours of dosing for receptor-level changes. healthspan and biological-age endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Clinical Protocol

Start a IGF-1 LR3 Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified IGF-1 LR3 and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 9111 Da
Sequence length: 83 aa
Half-life: ~20-30 hr (vs ~10 min for native IGF-1)
WADA: Banned (S2)
FDA: Unapproved (research reagent)
Research: Animal models; off-label use widespread

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for IGF-1 LR3 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for IGF-1 LR3

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised